A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
复制标题
DOI：
10.1053/j.gastro.2004.01.012
复制
发表时间：
2004-04-01
期刊：
影响因子：
29.4
通讯作者：
Kishimoto, T
中科院分区：
文献类型：
--
作者：
Ito, H;Takazoe, M;Kishimoto, T
背景与目的：白细胞介素-6（IL-6）调节免疫应答和炎症反应。我们进行了一项先导性安慰剂对照研究，以调查MRA（一种针对IL-6受体的人源化单克隆抗体）在活动性克罗恩病患者中的疗效、药代动力学和安全性。方法：36例活动性克罗恩病患者（克罗恩病活动指数[CDAI]），
Background & Aims: Interleukin-6 (IL-6) regulates immune response and inflammation. We carried out a pilot placebo-controlled study to investigate the efficacy, pharmacokinetics, and safety of MRA, a humanized monoclonal antibody to IL-6 receptor, in patients with active Crohn's disease. Methods: Thirty-six patients with active Crohn's disease (Crohn's Disease Activity Index [CDAI]